Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
AIDS and Behavior
Erschienen in: AIDS and Behavior 9/2013

01.11.2013 | Substantive Review

Effectiveness of Structural-Level Needle/Syringe Programs to Reduce HCV and HIV Infection Among People Who Inject Drugs: A Systematic Review

verfasst von: Abu S. Abdul-Quader, Jonathan Feelemyer, Shilpa Modi, Ellen S. Stein, Alya Briceno, Salaam Semaan, Tara Horvath, Gail E. Kennedy, Don C. Des Jarlais

Erschienen in: AIDS and Behavior | Ausgabe 9/2013

Einloggen, um Zugang zu erhalten

Abstract

Needle-syringe programs (NSP) have been effective in reducing HIV and hepatitis C (HCV) infection among people who inject drugs (PWID). Achieving sustainable reductions in these blood-borne infections requires addressing structural factors so PWID can legally access NSP services. Systematic literature searches collected information on NSP coverage and changes in HIV or HCV infection prevalence or incidence at the population level. Included studies had to document biomarkers (HIV or HCV) coupled with structural-level NSP, defined by a minimum 50 % coverage of PWID and distribution of 10 or more needles/syringe per PWID per year. Fifteen studies reported structural-level NSP and changes in HIV or HCV infection prevalence/incidence. Nine reported decreases in HIV prevalence, six in HCV infection prevalence, and three reported decreases in HIV incidence. The results support NSP as a structural-level intervention to reduce population-level infection and implementation of NSP for prevention and treatment of HIV and HCV infection.
Fußnoten
1
For locations in which study authors specified the number of PWID covered by the exchange, we used that percentage if greater than 50 % as rationale for a structural-level intervention (they also had to provide the number of syringes given). In cases that there was no coverage percentage given, we estimated coverage by taking the number of syringes distributed in the location (estimated or given outright by the author) divided by the number of PWID, and if that result was 10 or more syringes, we considered this to be a structural-level intervention. Finally, in some of the studies, authors not only gave percent coverage, but additionally provided syringe numbers and the number of PWID in the particular location. In these instances, we were able to not only document an estimate number of syringes per PWID, but also give an explicit value for coverage. If we could not establish coverage through the author directly or through supplementary searching, the study was not included in the review as we could not determine the program as structural or not.
 
2
Our coverage criteria were based on Vickerman et al. [21], which indicated threshold coverage of more than 20 % to affect substantial decreases in HIV prevalence.
 
Literatur
1.
Gerberding JL. Incidence and prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and cytomegalovirus among health care personnel at risk for blood exposure: final report from a longitudinal study. J Infect Dis. 1994;170(6):1410–7.PubMedCrossRef
2.
Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, Wodak A, Panda S, Tyndall M, Toufik A, Mattick RP, 2007 Reference Group to the UN on HIV and Injecting Drug Use. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372(9651):1733–45.PubMedCrossRef
3.
Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol. 2008;168(10):1099–109.PubMedCrossRef
4.
Palmateer N, Kimber J, Hickman M, Hutchinson S, Rhodes T, Goldberg D. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction. 2010;105(5):844–59.PubMedCrossRef
5.
Anderson E, Gans J, Shwayder P, Scofield J, Catizone C. HIV prevention and access to sterile syringes. National Center for HIV, STD and TB Prevention, Centers for Disease Control and Prevention. Atlanta; 1999.
6.
Centers for Disease Control. Report on pharmacy sales of sterile syringes. Atlanta; 2005.
7.
Sheridan J, Henderson C, Greenhill N, Smith A. Pharmacy-based needle exchange in New Zealand: a review of services. Harm Reduct J. 2005;2:10.PubMedCrossRef
8.
Wright-Deaguero L, Weinstein B, Jones TS, Mills J. Impact of the change in Connecticut syringe prescription laws on pharmacy sales and pharmacy managers’ practices. JAIDS. 1998;18(Supp l):S102–10.
9.
Valleroy LA, Weinstein B, Jones TS, Groseclose SL, Rolfs RT, Kassler WJ. Impact of increased legal access to needles and syringes on community pharmacies needle and syringe sales—Connecticut, 1992–1993. JAIDS. 1995;10:73–81.PubMed
10.
Somaini B, Wang J, Perozo M, Kuhn F, Meili D, Grob P, et al. A continuing concern: HIV and hepatitis testing and prevalence among drug users in substitution programmes in Zurich, Switzerland. AIDS Care. 2000;12(4):449–60.PubMedCrossRef
11.
Vlahov D, Robertson AM, Strathdee SA. Prevention of HIV infection among injection drug users in resource-limited settings. Clin Infect Dis. 2010;50(Suppl 3):S114–21.PubMedCrossRef
12.
Sumartojo E. Structural factors in HIV prevention: concepts, examples, and implications for research. AIDS. 2000;14(Suppl 1):S3–10.PubMedCrossRef
13.
Blankenship KM, Friedman SR, Dworkin S, Mantell JE. Structural interventions: concepts, challenges and opportunities for research. J Urban Health. 2006;83(1):59–72.PubMedCrossRef
14.
Rhodes T, Lilly R, Lalam N, Giorgino E, Kemmesis UE, Ossebaard HC, et al. Risk factors associated with drug use: the importance of risk environment. Drugs Educ Prev Policy. 2003;10(4):303–29.CrossRef
15.
Rhodes T, Singer M, Bourgois P, Friedman SR, Strathdee SA. The social structural production of HIV risk among injecting drug users. Soc Sci Med. 2005;61(5):1026–44.PubMedCrossRef
16.
Jones L, Pickering L, Sumnall H, McVeigh J, Bellis MA. Optimal provision of needle and syringe programmes for injecting drug users: a systematic review. Int J Drug Policy. 2010;21(5):335–42.PubMedCrossRef
17.
Wodak A, Cooney A. Effectiveness of sterile needle and syringe programming in reducing HIV/AIDS among injecting drug users. Evidence for Action Technical Papers. Geneva: WHO; 2004.
18.
Garu LE, Bluthenthal RN, Marshall P, Singer M, Heimer R. Psychosocial and behavioral differences among drug injectors who use and do not use syringe exchange programs. AIDS Behav. 2005;9(4):495–504.CrossRef
19.
Sharma M, Burrows D, Bluthenthal R. Coverage of HIV prevention programmes for injection drug users: confusions, aspirations, definitions and ways forward. Int J Drug Policy. 2007;18:92–8.PubMedCrossRef
20.
Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. 5th ed. West Sussex: The Cochrane Collaboration and Wiley; 2008.CrossRef
21.
Vickerman P, Hickman M, Rhodes T, Watts C. Model projections on the required coverage of syringe distribution to prevent HIV epidemics among injecting drug users. J Acquir Immune Defic Syndr. 2006;42(3):355–61.PubMedCrossRef
22.
23.
Denison JA, O’Reilly KR, Schmid GP, Kennedy CE, Sweat MD. HIV voluntary counseling and testing and behavioral risk reduction in developing countries: a meta-analysis, 1990–2005. AIDS Behav. 2008;12(3):363–73.PubMedCrossRef
24.
Kennedy CE, Spaulding AB, Brickley DB, Almers L, Mirjahangir J, Packel L, et al. Linking sexual and reproductive health and HIV interventions: a systematic review. J Int AIDS Soc. 2010;13:26.PubMedCrossRef
25.
Goldberg D, Cameron S, McMenamin J. Hepatitis C virus antibody prevalence among injecting drug users in Glasgow has fallen but remains high. Commun Dis Public Health. 1998;1(2):95–7.PubMed
26.
Goldberg D, Burns S, Taylor A, Cameron S, Hargreaves D, Hutchinson S. Trends in HCV prevalence among injecting drug users in Glasgow and Edinburgh during the era of needle/syringe exchange. Scand J Infect Dis. 2001;33(6):457–61.PubMedCrossRef
27.
Smyth BP, Keenan E, O’Connor JJ. Evaluation of the impact of Dublin’s expanded harm reduction programme on prevalence of hepatitis C among short-term injecting drug users. J Epidemiol Community Health. 1999;53(7):434–5.PubMedCrossRef
28.
Hope VD, Judd A, Hickman M, Sutton A, Stimson GV, Parry JV, et al. HIV prevalence among injecting drug users in England and Wales 1990 to 2003: evidence for increased transmission in recent years. AIDS. 2005;19(11):1207–14.PubMedCrossRef
29.
Ramirez-Jonville A. Drug addiction: harm reduction policies in France and Spain. Presse Med. 2006;35(7–8):1151–61.PubMedCrossRef
30.
Hammett TM, Kling R, Johnston P, Liu W, Ngu D, Friedmann P, et al. Patterns of HIV prevalence and HIV risk behaviors among injection drug users prior to and 24 months following implementation of cross-border HIV prevention interventions in northern Vietnam and southern China. AIDS Educ Prev. 2006;18(2):97–115.PubMedCrossRef
31.
Des Jarlais DC, Kling R, Hammett TM, Ngu D, Liu W, Chen Y, et al. Reducing HIV infection among new injecting drug users in the China-Vietnam Cross Border Project. AIDS. 2007;21(Suppl 8):S109–14.PubMedCrossRef
32.
Des Jarlais DC, Perlis T, Arasteh K, Torian LV, Beatrice S, Milliken J, et al. HIV incidence among injection drug users in New York City, 1990 to 2002: use of serologic test algorithm to assess expansion of HIV prevention services. Am J Public Health. 2005;95(8):1439–44.PubMedCrossRef
33.
Des Jarlais DC, Perlis T, Arasteh K, Torian LV, Hagan H, Beatrice S, et al. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990–2001. AIDS. 2005;19(Suppl 3):S20–5.PubMedCrossRef
34.
Des Jarlais DC, Arasteh K, Hagan H, McKnight C, Perlman DC, Friedman SR. Persistence and change in disparities in HIV infection among injection drug users in New York City after large-scale syringe exchange programs. Am J Public Health. 2009;99(Suppl 2):S445–51.PubMedCrossRef
35.
Des Jarlais DC, Arasteh K, McKnight C, Hagan H, Perlman D, Friedman SR. Using hepatitis C virus and herpes simplex virus-2 to track HIV among injecting drug users in New York City. Drug Alcohol Depend. 2009;101(1–2):88–91.PubMedCrossRef
36.
Des Jarlais DC, Arasteh K, McKnight C, Hagan H, Perlman DC, Torian LV, et al. HIV infection during limited versus combined HIV prevention programs for IDUs in New York City: the importance of transmission behaviors. Drug Alcohol Depend. 2010;109(1–3):154–60.PubMedCrossRef
37.
Kerr T, Small W, Buchner C, Zhang R, Li K, Montaner J, et al. Syringe sharing and HIV incidence among injection drug users and increased access to sterile syringes. Am J Public Health. 2010;100(8):1449–53.PubMedCrossRef
38.
Bruneau J, Daniel M, Abrahamowicz M, Zang G, Lamothe F, Vincelette J. Trends in human immunodeficiency virus incidence and risk behavior among injection drug users in Montreal, Canada: a 16-year longitudinal study. Am J Epidemiol. 2011;173(9):1049–58.PubMedCrossRef
39.
Topp L, Day CA, Iversen J, Wand H, Maher L. Fifteen years of HIV surveillance among people who inject drugs: the Australian Needle and Syringe Program Survey 1995–2009. AIDS. 2011;25(6):835–42.PubMedCrossRef
40.
Personal communication with Kerr on May 21 2010.
41.
Lurie P, Drucker E. An opportunity lost: HIV infections associated with lack of a national needle-exchange programme in the USA. Lancet. 1997;349(9052):604–8.PubMedCrossRef
42.
UNAIDS. Practical guidelines for intensifying HIV prevention: towards universal access. Geneva: UNAIDS; 2007.
43.
44.
Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364(25):2417–28.PubMedCrossRef
45.
Mathers BM, Degenhardt L, Ali H, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2010;375(9719):1014–28.PubMedCrossRef
Metadaten
Titel
Effectiveness of Structural-Level Needle/Syringe Programs to Reduce HCV and HIV Infection Among People Who Inject Drugs: A Systematic Review
verfasst von
Abu S. Abdul-Quader
Jonathan Feelemyer
Shilpa Modi
Ellen S. Stein
Alya Briceno
Salaam Semaan
Tara Horvath
Gail E. Kennedy
Don C. Des Jarlais
Publikationsdatum
01.11.2013
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 9/2013
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-013-0593-y

Weitere Artikel der Ausgabe 9/2013

AIDS and Behavior 9/2013 Zur Ausgabe

Brief Report

The LIVE Network: A Music-Based Messaging Program to Promote ART Adherence Self-Management

Original Paper

A Randomized Trial of a Behavioral Intervention for High Risk Substance-Using MSM

Original Paper

Personal Health Record Use and Its Association with Antiretroviral Adherence: Survey and Medical Record Data from 1871 US Veterans Infected with HIV

Original Paper

Supportive-Expressive and Coping Group Teletherapies for HIV-Infected Older Adults: A Randomized Clinical Trial

Original Paper

Who is Omitted from Repeated Offline HIV Behavioural Surveillance Among MSM? Implications for Interpreting Trends

Original Paper

A Randomized Controlled Trial of the Community-Friendly Health Recovery Program (CHRP) Among High-Risk Drug Users in Treatment

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise